The role of progestogen supplementation (dydrogesterone) in the prevention of preeclampsia

Abstract

Our goal was determine the effects of dydrogesterone supplementation to reduce the incidence of preeclampsia (PE) in early pregnancy (from 6 to 20 weeks of gestation). A total of 406 pregnant women were involved into the study. The Study group enrolled 169 women, supplemented with dydrogesterone at a dose of 30 mg/d 6–20 weeks of gestation compared with the control group (237 subjects) – without dydrogesterone supplementation. The women were randomized by age, race, obstetrics complications, and their somatic history. The use of dydrogesterone in early pregnancy – before 20 weeks of gestation (at a dose of 30 mg/d) with high-risk factors of PE contributed to a statistically significant reduction in the frequency of this complication (13.1% and 71.4%, p < .001). It was seen, that women who took dydrogesterone developed significantly less such disorders like hypertension (3.2% and 71.2%, p < .001), proteinuria (0.0% and 66.18%, p < .001), fetal growth retardation syndrome (2.2% and 21.58%, p < .001), destroy of uteri-placenta velocity (3.2% and 21.58%, p < .001), preterm labor (8.6% and 53.95%, p < .001). Dydrogesterone supplementation in the first and second period of pregnancy (from 6 to 20 weeks of gestation) significantly reduced the incidence of PE in women with higher risk pregnancy.

摘要

我们的目标是明确补充地屈孕酮对降低妊娠早期（妊娠6至20周）先兆子痫（PE）发病率的影响。共有406名孕妇参与了这项研究, 研究组招募了169名妇女, 与没有补充地屈孕酮的对照组（237名受试者）相比, 研究组在妊娠6-20周时以30 mg/d的剂量补充地屈孕酮。这些妇女按年龄, 种族, 产科并发症和躯体病史随机分组, 有PE高危因素的孕妇在妊娠早期-妊娠20周前使用地屈孕酮（剂量为30 mg/d）统计学上显着降低这种并发症的发生率（13.1%和71.4%, p<.001）。结果显示, 服用地屈孕酮的孕妇患高血压（3.2%和71.2%, p<.001）, 蛋白尿（0.0%和66.18%, p<.001）, 胎儿发育迟缓综合征（2.2%和21.58%, p<.001）, 子宫胎盘破坏速度（3.2%和21.58%, p<.001）, 早产（8.6%和53.95%, p<.001）等疾病的发生率明显降低。在妊娠的第一和第二阶段（妊娠6至20周）补充地屈孕酮显著降低了妊娠高危妇女的PE发病率。

The Chinese abstracts are translated by Prof. Dr. Xiangyan Ruan and her team: Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China.

Keywords:

• Preeclampsia
• prevention
• higher risk groups
• progestogen
• dydrogesterone

Disclosure statement

No potential conflict of interest was reported by the authors.